Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy

0493571 - ÚEM 2019 RIV US eng J - Journal Article
Catalano, C. - da Silva Filho, M.I. - Jirásková, Kateřina - Vymetálková, Veronika - Levý, M. - Liška, V. - Vyčítal, O. - Naccarati, Alessio - Vodičková, Ludmila - Hemminki, K. - Vodička, Pavel - Weber, A.N.R. - Försti, A.
Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
European Journal of Gastroenterology & Hepatology. Roč. 30, č. 8 (2018), s. 838-742. ISSN 0954-691X. E-ISSN 1473-5687
Institutional support: RVO:68378041
Keywords : 5-fluorouracil * colorectal cancer * NLRC5 * survival analysis
OECD category: Gastroenterology and hepatology
Impact factor: 2.198, year: 2018

Background NLRC5 is an interferon gamma-inducible protein, which plays a role in immune surveillance with a potential influence on cancer survival.

Objective We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients.

Patients and methods We carried out a case-only study in a Czech population of 589 cases, 232 received 5-FU-based therapy. Eleven variants within NLRC5 were selected using in-silico tools. Associations between polymorphisms and survival were assessed by Cox regression analysis adjusting for age at diagnosis, sex, and TNM stage. Survival curves were derived using the Kaplan-Meier method.

Results Two variants showed a significant association with survival. All patients and metastasis-free patients at the time of diagnosis (pM0) who were homozygous carriers of the minor allele of rs27194 had a decreased overall survival (OSall and OSpM0) and event-free survival (EFSpM0) under a recessive model (OSall P=0.003, OSpM0 P=0.005, EFSpM0 P=0.01, respectively). OS was also decreased for all patients and for pM0 patients who carried at least one minor allele of rs289747 (OSall P=0.03 and OSpM0 P=0.003, respectively). Among CRC patients, who underwent a 5-FU-based adjuvant regimen, rs12445252 was associated with OSall, OSpM0 and EFSpM0, according to the dosage of the minor allele T (OSall P=0.0004, OSpM0 P=0.0001, EFSpM0 P=0.008, respectively).

Conclusion Our results showed that polymorphisms in NLRC5 may be used as prognostic markers of survival of CRC patients, as well as for survival in response to 5-FU treatment.
Permanent Link: http://hdl.handle.net/11104/0286914